The sirtuins (SIRT 1-7) comprise a family of NAD þ -dependent protein-modifying enzymes with activities in lysine deacetylation, adenosinediphospho(ADP)-ribosylation, and/or deacylation. These enzymes are involved in the cell's stress response systems and in regulating gene expression, DNA damage repair, metabolism and survival. Sirtuins have complex roles in both promoting and/or suppressing tumorigenesis. This review presents recent research progress concerning sirtuins and cancer. On one hand, functional loss of sirtuin genes, particularly SIRT1, involved in maintaining genome integrity and DNA repair will promote tumorigenesis because of genomic instability upon their loss. On the other hand, cancer cells tend to require sirtuins for these same processes to allow them to survive, proliferate, repair the otherwise catastrophic genomic events and evolve. The bifurcated roles of SIRT1, and perhaps several other sirtuins, in cancer may be in part a result of the nature of the genes that are involved in the cell's genome maintenance systems. The in-depth understanding of sirtuin functions may have significant implication in designing precise modulation of selective sirtuin members to aid cancer prevention or treatment under defined conditions.
INTRODUCTION
Sirtuins are mammalian homologs of yeast silent information regulator 2 (Sir2) encoding a histone deacetylase. 1, 2 The seven mammalian members of sirtuins (termed SIRT1-7) share a conserved catalytic core domain ( Figure 1 ). Despite this homology, sirtuins have divergent enzymatic activities with SIRT1-3 and SIRT7 primarily as lysine deacetylases, SIRT4 primarily as adenosinediphospho (ADP)-ribosyltransferase, SIRT5 as deacetylase and deacylase, and SIRT6 as ADP-ribosyltransferase and deacetylase. [1] [2] [3] [4] [5] In addition, primary localization of these proteins in the cell varies significantly, reflecting functional distinction of sirtuin members (see Figure 1) .
Growing interest in sirtuins largely stems from previous studies of yeast Sir2 showing that in lower organisms, increased Sir2 gene dosage is sufficient to extend lifespan, [6] [7] [8] and that Sir2 is at a nexus between caloric restriction, resveratrol or other caloric restriction mimetics and longevity. 9, 10 More recently, these initial observations have been scrutinized and refined to show a lack of an effect of Sir2 in extending lifespan in lower species as well as in mammals. [11] [12] [13] Further adding to the complex nature of the role of sirtuins in extending lifespan, Kanfi et al.
14 described that transgenic SIRT6 male mice live B10-15% longer than their wild-type littermates. The conflicting literature on the roles of Sir2 in longevity contributes in part to the confusion of functions of mammalian sirtuins, but may also foretell the complexity of these genes in mammalian cells.
Research in the past decade has revealed the perplexed and often controversial roles of sirtuins in promoting versus suppressing cancer. Cancer cells alter normal cellular machineries to promote unabated cell proliferation and maximize their lifespan, but as a consequence of their malignant growth, they cut short the lifespan of the host organism. Hanahan and Weinberg 15 have elegantly outlined the fundamental mechanisms of cancer promotion as consisting of sustaining proliferative signaling, enabling replicative immortality, activating invasion and metastasis and inducing angiogenesis; meanwhile, as normal cells possess innate mechanisms to antagonize cancer-promoting signals, the transformed cells must also overcome tumor suppression mechanisms, namely, by evading growth suppressor signals and resisting cell death. Crucially underlying these hallmarks of cancer is the genetic instability of cancer cells. 15 Although cancer biologists tend to classify genes into either tumor promoting or tumor suppressing, only a limited number of genes unambiguously fall into one of these categories, for examples, MYC as an oncogene and retinoblastoma gene RB as a tumor suppressor gene. 16 Other genes including sirtuins are less apparent, and the tumor-promoting or -inhibiting properties of the genes may depend on the stages of cancer development and contextual variables such as tissue of origin, the microenvironment and the exact experimental conditions. 15 However, rapid progress has been made most recently in the research on mammalian sirtuins and cancer, which may improve our understanding of these elusive genes and will be highlighted in this review.
SIRT1
Biochemical overview SIRT1 shares the greatest homology with yeast Sir2, which was initially characterized as an nicotinamide adenine dinucleotide (NAD) þ -dependent histone deacetylase 2 (so-called class III histone deacetylase that is structurally and biochemically distinct from class I, II and IV histone deacetylases). SIRT1 deacetylates histone H4 lysine 16 (H4K16) as well as histone H3 lysine 9 and 14 (H3K9 and H3K14, respectively). 1 Additionally, SIRT1 deacetylates histone H1 lysine 26 (H1K26) and is involved in the deposition of histone variants. 17 These modifications of histone tails are closely related to gene silencing and heterochromatin formation that may underlie certain biological processes. 18, 19 Notably, global genomic hypoacetylation at H4K16 is a hallmark of human cancer cells, both cell lines and clinical samples. 20 The biological roles of SIRT1, however, are mostly revealed through its deacetylation of a growing number of non-histone substrates that are involved in a wide variety of cellular functions, particularly in metabolic, oxidative/genotoxic and oncogenic stress responses. These substrates can be broadly categorized as: (1) transcriptional factors p53, forkhead transcription factors (FOXO)1, FOXO3a, nuclear factor (NF)-kB, c-MYC, N-MYC, E2F1 and hypoxia-inducible transcription factors (HIF)-1a/HIF-2a, for regulating cell cycle progression and promoting survival under various conditions; (2) DNA repair machinery elements Ku70, RAD51, NBS1, APE1, XPA/C and WRN, for improving DNA damage repair; (3) nuclear receptor, circadian clock and related factors LXR, FXR, ERa, AR, PPARg, PGC1a, CLOCK and PER2, for regulating metabolism; (4) histone-modifying enzymes SUV39H1, p300, TIP60 and PCAF, for regulating gene expression; (5) cell-signaling molecules STAT3, b-catenin and SMAD7, as detailed in previous reviews. 21, 22 SIRT1, genetic stability and tumor suppression Several studies using mouse models provide evidence that SIRT1 may improve genetic stability and suppress tumor formation (Table 1) . SIRT1 is a critical gene for mouse early development. Homozygous deletion of SIRT1 (DExon5-6 or DExon5-7) results in perinatal and postnatal lethality in C57BL/6 and 129 strains. 23, 24 More severe and early embryonic lethality phenotype occurs in another strain with mixed genetic background containing FVB upon SIRT1 deletion (DExon5-6). 25 In C57BL/6-129 background, wild-type and SIRT1
À / À mouse embryonic stem cells exhibit similar levels of chromosomal abnormality, but SIRT1 À / À embryonic stem cells are more prone to genomic instability under oxidative stress. 26 In mixed FVB background, SIRT1
À / À early embryos and mouse embryonic fibroblasts display markedly increased spontaneous gross chromosomal abnormalities accompanied with altered global histone modifications. 25 The genetic instability in SIRT1
À / À embryonic cells is attributed to defective DNA damage repair characterized by reduced gH2AX foci formation and reduced recruitment of DNA-damage repair factors to the foci. 25, 26 In accord with reduced genetic stability upon SIRT1 loss, SIRT1 heterozygous deletion accelerates tumor formation in p53 þ / À knock-out mice. 25 Using a conditional SIRT1 overexpression allele that is specifically expressed in the cells lining the intestine, Firestein et al. 27 showed that SIRT1 overexpression reduces intestinal tumor formation in adenomatous polyposis coli (APC) min/ þ mice. They demonstrated that SIRT1 deacetylates b-catenin and reduces its nuclear presence and transactivation potential. Similarly, Oberdoerffer et al. 26 showed that SIRT1 conditional overexpression reduces tumor burden in p53 þ / À mice. In a recent report, Herranz et al.
11 undertook a 3-year study of SIRT1 transgenic mice with SIRT1 overexpression under its own promoter, and showed that increased SIRT1 expression by threefold improves healthy mouse aging and reduces spontaneous carcinomas and sarcomas, as well as carcinogeninduced liver cancer incidence. Taken together, in vivo mouse models suggest that SIRT1 may improve genetic stability of normal cells and suppress tumor formation.
In addition to genetic stability, SIRT1 may regulate other pathways that contribute to its tumor suppression function. SIRT1 has been shown to inhibit the NF-kB pathway 28 that promotes inflammation, survival and cancer metastasis. 29 NF-kB comprises heterodimers with p65 and p50 subunits. SIRT1 deacetylates the p65/Rel-A subunit of NF-kB and blocks its transactivation of downstream anti-apoptotic target genes, cIAP-2 and BCL-xL.
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Further in line with tumor suppressor function, SIRT1 acts downstream of BReast CAncer 1 (BRCA1) to negatively regulate the anti-apoptotic gene, Survivin, by deacetylating H3K9 on its promoter and thereby repressing its transcription. Thus, BRCA1 ablation, via reduced SIRT1, results in elevated Survivin levels and enhances tumor growth. 30 Dysregulation of SIRT1 gene expression and enzymatic activity in cancer Although SIRT1 has tumor suppression function in the mouse studies described above, so far there is no reported functional SIRT1 genetic mutation or deletion, or SIRT1 promoter hypermethylation in human cancer. 42 observed reduction of SIRT1 expression, but Nosho et al. 43 showed that SIRT1 overexpression correlates with microsatellite instability as well as a CpG island methylator phenotype. Similarly, in mice, overexpression of SIRT1 is reported in leukemia, lymphoma, sarcoma, lung adenocarcinoma and prostate cancer. 34, 39, 44, 45 Alteration of SIRT1 gene expression in cancer is mediated by multiple mechanisms affecting transcription, translation and posttranslational modifications. At the transcriptional level, tumor suppressor HIC1 directly represses SIRT1 transcription, thereby leading to acetylation and activation of another tumor suppressor p53 (Chen et al., 44 and Figure 2 ). Loss of HIC1 results in deacetylation of p53 and survival of aged and damaged cells, which may predispose them to cancers. 46, 47 p53 itself has been shown to directly repress SIRT1 transcription as well. 48 Conversely, SIRT1 is upregulated by oncogenic transformation in several settings. Yuan et al. 39 have recently shown that transformation of hematopoietic stem/progenitor cells by oncogenic tyrosine kinase BCR-ABL activates SIRT1 transcription in part through STAT5 (signal transducer and activator of transcription 5). STAT5 is downstream of numerous cytokine and growth factor receptorsignaling cascades and is constitutively active in many cancer types. 49 STAT5 also acts downstream of BCR-ABL protein in chronic myelogenous leukemia (CML). 50, 51 STAT5 directly binds the SIRT1 promoter and enhances SIRT1 expression in CML cells 39 (see Figure 2 ). SIRT1 levels are increased stepwise from normal hematopoietic cells to chronic-phase CML to accelerated and blast crisis CML. 39 In the same setting, Yuan et al. 39 also showed that SIRT1 can be activated by KRAS transformation. Recently, several groups have demonstrated that MYC (c-MYC and N-MYC) protooncogenes directly activates SIRT1 transcription. 52, 54 This occurs despite incomplete agreement of its effect on MYC protein stability: three groups showing that SIRT1 and MYC form a positive feedback loop in which SIRT1 deacetylates MYC and enhances MYC protein stability, 52, 54, 55 whereas another group showing that SIRT1 destabilizes c-MYC protein. 53 In addition, the cell cycle and apoptosis regulator E2F1 induces SIRT1 transcription when cancer cells are under genotoxic stress. 56 At the message level, SIRT1 expression is increased by stabilizing its messenger RNA (mRNA) in cancer cells. MicroRNAs are small, RNA polymerase II-transcribed genes that generally form clusters and operate by binding to the 3 0 untranslated regions of genes and thereby negatively regulating mRNA stability and/or translation. 57 Several families of microRNAs have been shown to negatively regulate SIRT1, particularly miR-34a. 58 The chromosomal region where miR-34a resides is frequently lost in human cancers, while reintroduction of miR-34a into cancer cells triggers apoptosis. 59, 60 Other miR families including miR-200a that target SIRT1 have been characterized as possessing tumor suppressor function. 32, 57, 61 Conversely, SIRT1 mRNA is stabilized by RNA-binding protein HuR 62 , which has a role in promoting tumor cell proliferation and survival. [63] [64] [65] SIRT1 protein stability is regulated by phosphorylation, sumoylation and ubiquitination. SIRT1 phosphorylation by cell cycledependent kinase cyclin B/CDK1 controls cell proliferation. 66 The dual specificity tyrosine phosphorylation-regulated kinases DYRK1A and DYRK3 phosphorylate SIRT1 and increase SIRT1 enzymatic activity to promote cell survival.
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SIRT1 phosphorylation by c-Jun N-terminal kinase 2 stabilizes the protein, 68 whereas SIRT1 phosphorylation by JNK1 facilitates ubiqitination-mediated degradation. 69 Under genotoxic stress, the proapoptotic nuclear desumoylase SENP1 removes SIRT1 sumoylation and reduces its deacetylase activity. 70 Finally, SIRT1 enzymatic activity could be regulated during tumorigenesis. Deleted in breast cancer 1 (DBC1) is a tumor suppressor that is lost in a portion of breast cancer patients. DBC1 suppresses SIRT1 activity by direct binding to the SIRT1 catalytic core domain. 71, 72 In contrast, active regulator of SIRT1 (AROS) increases SIRT1 activity through direct interaction with N-terminus of SIRT1 protein. 73 Furthermore, increasing SIRT1 expression is concomitant with activation of the mammalian NAD þ salvage biosynthesis enzyme nicotinamide phosphoribosyltransferase in several types of cancer cells to provide sufficient NAD þ for SIRT1 functions, which is important for cancer cell survival and stress response. 52, 74 SIRT1 promotes cancer genomic instability and cancer evolution Several recent studies provide crucial insight into the roles of SIRT1 dysregulation in cancer. Yuan et al. 39 demonstrated that SIRT1 homozygous knockout significantly inhibits BCR-ABL transformation of mouse bone marrow stem/progenitor cells À / À mice and transduced by BCR-ABL in vitro, followed by transplantation to lethally irradiated syngenic recipients. The effect of SIRT1 knockout on leukemogenesis is thus not influenced by SIRT1 loss on mice, but is a result of cell autonomous impact on leukemia cells. Pharmacological inhibition of SIRT1 also inhibits leukemia development to a similar extent as SIRT1 knockout. This study provides the first genetic evidence for a causal role of dysregulated SIRT1 expression in efficient oncogenic transformation and leukemia progression.
In another study, Herranz et al. 75 crossed SIRT1 transgenic mice to PTEN þ / À mice, and found that SIRT1 overexpression increased incidence of thyroid carcinomas and their lung metastasis, suggesting that increased SIRT1 gene expression has a direct role in promoting tumor progression. These authors found that SIRT1 enhanced Myc stability, although they did not directly link deacetylation of Myc to protein stability. Furthermore, Herranz et al. 75 showed that PTEN þ / À SIRT1 transgenic mice also developed prostate carcinomas in situ, whereas PTEN þ / À or SIRT1 transgenic cohort mice did not, indicating that SIRT1 overexpression may also have a role in promoting tumor initiation. This study provides additional genetic evidence that SIRT1 activation can facilitate tumorigenesis.
The above studies ostensibly contrast other mouse genetic studies suggesting roles of SIRT1 in tumor suppression, as described above. The precise mechanisms for this difference are not clear, but recent studies raise the possibility that SIRT1 might differentially regulate genomic stability in normal versus cancer cells (Figure 3) . In normal cells, loss of SIRT1 causes defective DNA repair leading to genomic instability. Intriguingly, in cancer cells, SIRT1 knockdown also reduces the efficiency of DNA damage repair including both non-homologous end joining (NHEJ) and homologous recombination (HR) repair in CML cells 76 and osteosarcoma cells. 26 It is shown that SIRT1 is recruited to sites of DNA damage, presumably to remodel local chromatin structure to facilitate repair in cancer cells. 77, 78 Therefore, it is likely that SIRT1 may have a role in genome maintenance in both normal and cancer cells. However, this may lead to complex outcomes in cancer cells. On one hand, the maintenance by SIRT1 may ensure cancer cell survival and proliferation (see more in next section) by avoiding deleterious impact of DNA damage on key oncogenes, given that transformation is accompanied with increased production of reactive oxygen species (ROS) and oxidative DNA damage. 79, 80 On the other hand, increased DNA repair by SIRT1 could lead to more mutations in cancer cells and further genomic instability for cancer evolution. This is supported by a recent report by Wang et al. 76 , showing that SIRT1 promotes de novo acquisition of genetic mutations for drug resistance in CML and prostate cancer cells upon therapeutic (by tyrosine kinase inhibitors) and/or genotoxic (by camptothecin) stress. SIRT1 promotion of mutation acquisition is associated with its ability to increase error-prone DNA damage repair in cancer cells, in particular, through deacetylating the key NHEJ repair factor Ku70. Wang et al. 76 proposed that the unusual effect of SIRT1 in mutation promotion may be attributed to the compromised DNA repair fidelity in cancer cells, 81, 82 and thus new genetic mutations may arise as a consequence of misrepair under stress.
Genomic instability is one of the most critical enabling characteristics of cancer. As cancer progresses toward highergrade malignancy, more mutations are acquired, but mechanisms for such increasing mutation acquisition are not well understood. 15 The new findings by Wang et al. 76 may suggest a previously underestimated pathway for cancer genomic instability and evolution, that is, to accumulate mutations through enhanced infidelity DNA repair, which has important biological significance for cancer drug resistance. SIRT1 appears to be at the center of such an evolution pathway; 83 however, more detailed mechanisms still need to be worked out in the future.
SIRT1 promotes cancer hallmark capability Cancer evolves not only with accumulation of genetic alterations, but also with profound epigenetic changes. Cancer cells display global genomic DNA hypomethylation with concurrent hypermethylation at tumor suppressor gene loci. In addition, cancer cells display gross aberrant histone modification patterns relative to normal cells. 84 In addition to SIRT1 directly deacetylating 86, 87 The catalytic subunit of the PRC II complex is EZH2, which is responsible for trimethylation of H3K27 88 and itself a noted protooncogene frequently mutated in human cancers. 89 SIRT1 directly complexes with EZH2 and other components of the PRC complex and is an integral part of the PRC's silencing functions. 90 Kuzmichev et al. 45 identified a SIRT1-containing PRC complex, termed PRC4, which is specifically found in transformed cells and embryonic stem cells. Inhibition of SIRT1 has been shown to reactivate silenced tumor suppressor genes. 91 In addition, SIRT1 interacts and deacetylates the SUV39H1 methyltransferase, promoting histone H3 methylation and fostering heterochromatin formation 92 and repressing ribosomal RNA transcription to protect cells from energy deprivationdependent apoptosis. 93 The dysregulated epigenome by SIRT1 in cancer cells may act in concert with genetic alterations to facilitate cancer evolution and reach the biological endpoint hallmarks. 15 This section will discuss the cancer hallmarks that are affected by SIRT1.
Cancer hallmark 1: resisting cell death. SIRT1 regulates multiple cell death pathways. SIRT1 deacetylates p53 at lysine 382, reducing its transcriptional activity and leading to a blockade of p53-dependent apoptosis in response to DNA damage signals. 94, 95 Similar patterns are observed for p73, which is part of the p53 family. 96 Leukemia stem cells are typically refractory to chemotherapy. Recently, Li et al. 40 have demonstrated that inhibiting SIRT1 in CD34 þ CML stem/progenitor cells results in enhanced p53 acetylation, transcriptional activity and apoptosis of these cells, and sensitizes them to the BCR-ABL inhibitor, imatinib, both in vitro and in vivo. This effect is dependent on p53, as cells with p53 knockdown fail to respond to SIRT1 inhibition. This study reveals a novel drug resistance mechanism mediated by SIRT1 in leukemia stem cells.
The intrinsic apoptotic pathway is tightly orchestrated by the BCL-2 family, which contains pro-and anti-apoptotic members, of which Bax is the prototypical pro-apoptotic gene. 97 Cancer cells can resist apoptosis by sequestering Bax from mitochondria. This is accomplished through the non-canonical action of Ku70.
98 SIRT1 regulates Bax sequestration through deacetylation of Ku70, thereby increasing Ku70 interaction with Bax and blocking Bax translocation to mitochondria. 99 By modulating Ku70, SIRT1 inhibition induces apoptosis in leukemia cells lacking p53 in vitro and suppresses growth of tumor xenograft in vivo.
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The transcriptional regulator BCL6 is also subjected to deacetylation by SIRT1. 100 BCL6 is expressed in the germinal center within lymph nodes and represses genes that are involved in cell cycle regulation, apoptosis and differentiation. 101 Translocations involving BCL6 are a frequent event in B-cell lymphomas. 102, 103 Deacetylation by SIRT1 promotes BCL6 transcriptional repression activity and resists cell apoptosis. 100 Heltweg et al. 104 demonstrate that a chemical inhibitor of SIRT1, cambinol, has anti-lymphoma properties in vitro and in vivo in part by preventing the deacetylation and activation of BCL6.
As described above, SIRT1 can promote cancer cell death resistance by facilitating acquisition of genetic mutations. 76 In addition, SIRT1 promotes chemotherapy resistance by enhancing efflux of drugs. Chu et al. 105 report that SIRT1 is elevated in drugresistant cell lines as well as in patient samples. SIRT1 increases the expression of multidrug resistance 1 in cancer cells, whereas inhibition of SIRT1 sensitizes these cancer cells to anticancer drugs. Another group reported that a novel SIRT1 inhibitor, Amurensin G, reduces expression of multidrug resistance 1 and sensitizes otherwise resistant cells to cytotoxic drugs. 106 Cancer hallmark 2: sustaining proliferation signaling. As discussed above, SIRT1 is activated by MYC and forms a positive feedback loop to stabilize MYC protein in most studies. Stabilized MYC further enables cell proliferative signaling and stimulates cell growth. This likely explains why Burkitt's lymphoma, which is initiated by c-MYC transformation, is most sensitive to the SIRT1 inhibitor cambinol used as a single agent.
104 SIRT1 is also shown to regulate WNT signaling, 107 and WNT activation is associated with transcriptional activation of c-MYC in high-grade malignancy of colorectal cancer in the serrated route. 108 Cancer hallmark 3: evading growth suppressors. As described above, SIRT1 deacetylates and inactivates p53, a negative cell cycle regulator, to bypass growth arrest. Another key tumor suppressor family that is deacetylated by SIRT1 is the FOXO. [109] [110] [111] [112] FOXO transcription factors are involved in cell cycle control 113 as well as antioxidant and DNA-damage repair pathways. 114 Motta et al. 110 showed that SIRT1 deacetylation of FOXO3a suppresses FOXO3-mediated cell apoptosis induction, in parallel to p53 inhibition. Wang et al. 115 showed that deacetylation of FOXO3 by SIRT1 or SIRT2 results in its ubiquitination and subsequent degradation, thereby facilitating cell cycle progression and contributing to the promotion of cancer.
Cancer hallmark 4: inducing angiogenesis. It is known that SIRT1 controls endothelial angiogenic functions through deacetylating FOXO1 and notch1 intracellular domain during vascular growth.
116,117 SIRT1 enhances tumor angiogenesis through negatively modulating d-like ligand 4 (DLL4)/notch signaling in Lewis lung carcinoma xenograft-derived vascular endothelial cells.
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SIRT1 also activates endothelial nitric oxide synthase by deacetylation to enhance nitric oxide production and improve vascular function. 119 Cancer hallmark 5: activating invasion and metastasis. Epithelialto-mesenchymal transition (EMT) is an essential process to promote cancer invasion and metastasis. It has been shown that SIRT1 is activated during EMT-like transformation of mammary epithelial cells, in part due to epigenetic silencing of miR-200a, which negatively regulates SIRT1.
32 SIRT1 is also a positive regulator of EMT and metastasis of prostate cancer. 120 Overexpression of SIRT1 induces EMT through transcription factor ZEB1 in prostate cancer cells; SIRT1 knockdown restores cell-cell adhesion and reverses EMT of prostate cancer cells in vitro and in vivo.
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Cancer hallmark 6: deregulating cellular energetics and tumor microenvironment. The HIF-1 and HIF-2 are activated in cancer cells because of chronically low oxygen tension in the tumor bulk. HIF-1 activates numerous genes that promote angiogenesis, survival and glucose uptake, all necessary for tumor growth. HIF-1 is emerging as a major player in metastasis, chemo-and radiotherapy resistance. 121 HIF-1a is the regulatory subunit of HIF-1 and is subjected to post-translational modification. 122, 123 Lim et al. 124 showed that SIRT1 can deacetylate HIF-1a and repress its biological function in vitro and in tumor xenografts. However, such effect of SIRT1 on HIF-1a has been recently disputed by Laemmle et al., 125 showing that SIRT1 stabilizes HIF-1a under hypoxia and SIRT1 inhibition impairs hypoxic response of hepatocellular carcinoma cells. The study by Laemmle et al., 125 is in line with a previous report demonstrating that SIRT1 helps cells survive against hypoxic environment by activating HIF-2a. 126 Functions of sirtuins in cancer M Roth and WY Chen Summary of SIRT1 and cancer All the data so far suggest that SIRT1 has both pro-and anticancer roles. We propose that SIRT1 may act as a genome caretaker in normal cells, and therefore suppress tumorigenesis. However, upon oncogenic events, tumor cells co-opt SIRT1-regulated cellular pathways to promote unabated proliferation, progression, resisting death signals and genetic/epigenetic evolution. Such dual roles in tumorigenesis are not unprecedented. For examples, telomerase reverse transcriptase (TERT) can both hinder and promote tumor formation; 16 Transforming growth factor-b can be antiproliferative, but is redirected toward promoting EMT and high-grade malignancy at the later stages of tumorigenesis; 127 aberrant DNA hypermethylation by DNA methyltransferase 1 promotes tumorigenesis by silencing tumor suppressor genes, but DNA methyltransferase 1 deletion or expression of a hypomorphic allele in mice results in tumorigenesis. 128, 129 As such, the precise role of SIRT1 in tumorigenesis may be dependent on cellular and molecular contexts.
SIRT2
Biochemical overview SIRT2 shares certain biochemical parallels with SIRT1. SIRT2 has thus far been characterized primarily as an NAD þ -dependent protein deacetylase. Although being mostly cytoplasmic, SIRT2 can translocate to the nucleus where it deacetylates H4K16 during mitosis. 130, 131 SIRT2 has also been shown to deacetylate H3K56. 132 Much fewer non-histone substrates have thus far been identified for SIRT2. a-tubulin is the first known SIRT2 substrate, 133 but the exact biological role of tubulin acetylation/deacetylation remains elusive. Sharing substrates with SIRT1, SIRT2 also deacetylates FOXO1, 134, 135 FOXO3 115, 136 and p53 [137] [138] [139] for regulating autophagy, apoptosis and differentiation. Most recently, SIRT2 is shown to regulate programmed necrosis by targeting receptorinteracting proteins. 140 Mitotic regulation is another biological function frequently ascribed to SIRT2, as detailed in a previous review. 141 Kim et al. 142 described that SIRT2 regulates mitosis by deacetylating components of the anaphase-promoting complex/ cyclosome ubiquitin ligase machinery to enhance its activity, directing degradation of aurora kinases as cells exit mitosis. In the dietary obesity setting, the intra-adipose tissue hypoxia and activation of HIF-1a results in transcriptional repression of SIRT2, leading to increased acetylation of PGC-1a, and affecting b-oxidation and mitochondrial gene expression.
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SIRT2 and cancer Analogous to the bifurcated results with SIRT1 in cancer, SIRT2 has both roles in tumor suppression and promotion. SIRT2 is reported to be a tumor suppressor in gliomas 144, 145 and melanomas, 146 with chromosomal loss at the SIRT2 locus and point mutations within the catalytic domain that abrogates its enzymatic activity. SIRT2 expression is reduced in certain cancers, 142, 145, 147 and gene silencing by histone deacetylation is associated with SIRT2 downregulation in glioma cells. 148 However, forced SIRT2 expression only moderately reduces proliferation of glioma cells. 149 The direct support of SIRT2's tumor suppressor role is provided by Kim et al., 142 showing that SIRT2 knock-out mice develop tumors in various organs due to abnormal chromosomal segregation and aneuploidy caused by increased expression of mitotic regulators including aurora kinases upon SIRT2 knockout.
On the other hand, it is observed that SIRT2 may promote oncogenic phenotypes. SIRT2 is increased in acute myeloid leukemia cells compared with normal bone marrow cells, and SIRT2 inhibition causes apoptosis of acute myeloid leukemia cells in vitro. 150 Hou et al. 151 showed that SIRT2 expression positively correlates with cortactin in high-grade prostate cancer samples and predicts poor prognosis. Knockdown of SIRT2 induces p53 accumulation and promotes apoptosis of cancer cells. 138, 139 Recently, Liu et al. 152 showed that SIRT2 is activated by N-MYC in neuroblastoma cells and by c-MYC in pancreatic cancer cells. Activated SIRT2 stabilizes N-MYC and c-MYC protein and promotes cell proliferation through downregulating ubiquitin-protein ligase NEDD4. Liu et al. 152 also found that SIRT2 increases Aurora A expression in these cells, in contrast to the finding by Kim et al. 142 In this regard, it is worthy to note that Aurora A has bifurcated roles in cancer with either gene overexpression or knockout promoting tumorigenesis. 153, 154 More studies are needed to further delineate the precise roles of SIRT2 in cancer.
SIRT3
Biochemical overview SIRT3 possesses NAD þ -dependent deacetylase as well as ADPribosyltransferase activity. SIRT3 is the major mitochondrial deacetylase with a broad range of substrates. 155 Although principally localized to mitochondria, SIRT3 can be detected in the nucleus as well. 156 There are two forms of SIRT3, and processing of the N-terminus results in a smaller protein that localizes to mitochondria. 157, 158 Within the nucleus, SIRT3 deacetylates H4K16 and H3K9 to repress transcription. 156 In mitochondria, SIRT3 regulates metabolism, energy homeostasis, thermogenesis and mitochondrial biogenesis. For a more thorough review on SIRT3 and metabolic regulation, we refer the readers to other reviews. 159, 160 SIRT3 increases fatty acid b-oxidation by deacetylating, and therefore enhancing the activity of long-chain acyl CoA dehydrogenase. 161 The catabolism of fatty acids by boxidation yields acetyl CoA, which gets further metabolized by the Kreb's cycle. SIRT3 regulates several components of the Kreb's cycle and electron transport chain to promote adenosine triphosphate production. 160, 162 This is punctuated by the phenotype seen in SIRT3 knock-out mice that show reduced cellular adenosine triphosphate levels as well as increased ROS. 162 Uncontrolled ROS in the cell results in DNA and protein damage, aging and cancer.
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SIRT3 and cancer SIRT3 acts like a tumor suppressor as evidenced by increased mammary tumor formation in SIRT3 knock-out mice. 164 One major tumor suppression mechanism of SIRT3 is through modulation of ROS. As noted above, SIRT3
À / À cells show increased ROS due to faulty electron transport. 162, 164, 165 Another means by which SIRT3 regulates ROS is through the activation of antioxidant enzymes, such as superoxide dismutase that is a major mitochondrial detoxifying enzyme. 166, 167 Further, Someya et al. 168 revealed that SIRT3 lowers ROS by deacetylation and activation of mitochondrial isocitrate dehydrogenase 2, which in turn increases NADPH levels and the abundance of active glutathione, a major cellular antioxidant. Deacetylation and activation of FOXO3a by SIRT3 also promotes its activation of antioxidant enzymes. 169 Yet another mechanism whereby SIRT3 reduces ROS, and therefore tumorigenesis is in its capacity to destabilize HIF-1a. 165, 170 Because of SIRT3's effect in regulating oxidative phosphorylation and HIF-1, SIRT3
À / À cells may be further prone to cancer by shifting its metabolism toward aerobic glycolysis, a phenomenon termed the Warburg effect, which is thematic of most cancer cells. 171, 172 The studies with SIRT3 knock-out mice lend credence to the notion that SIRT3 acts to protect against tumorigenesis. However, it is unclear why SIRT3 knockout only increases mouse mammary tumors, given that these pathways are not mammary gland-specific.
In human cancers, Kim et al. 164 showed that SIRT3 protein and mRNA are reduced in breast cancer. Consistently, Bell et al. 165 showed that knockdown of SIRT3 in human cancer cells increases tumors size and reduces latency when injected into mice. Conversely, forced expression of SIRT3 blocks proliferation and reduces tumor xenografts. Finley et al. 170 found that about 20% of Skp2 is overexpressed in a wide range of cancers, and its expression levels foretell a poor clinical prognosis. Skp2 functions biochemically as an E3 ubiquitin ligase and is responsible for targeting numerous tumor suppressors such as p21 and p27 for proteasome-mediated degradation. 174 Deacetylation of Skp2 by SIRT3 leads to its nuclear import where Skp2 is excluded from targeting E-cadherin. In contrast, acetylated Skp2 gets exported to the cytoplasm where it ubiquitinates E-cadherin for proteasome-mediated degradation. 173 Reduced E-cadherin is observed in many cancers and is a feature of EMT and cancer metastases. 175 Together, these studies indicate that SIRT3 suppresses tumorigenesis.
Yet, as with SIRT1 and SIRT2, there are opposing studies that propose a tumor-promoting role for SIRT3. Alhazzazi et al. 176 showed that SIRT3 levels are elevated in oral squamous carcinoma cell lines and patient samples, and that knockdown of SIRT3 in OSCC lines reduces cell viability and proliferation as well as tumors in xenografts. Ectopic SIRT3 expression reverses p53-induced cell cycle arrest and senescence, which would provide a mechanism for a tumor-promoting role of SIRT3. 177 Like SIRT1, SIRT3 can deacetylate Ku70 and thereby facilitate its interaction with Bax to mitigate Bax-mediated apoptosis. 178 These studies, albeit few and contradictory, provide some evidence that SIRT3 may have a cellprotective role under stress and may give cancer cells a growth advantage.
SIRT4
SIRT4 is a mitochondrial ADP-ribosyltransferase without recognized deacetylase activity. Its primary function thus far uncovered is in regulation of metabolic function. In vitro, SIRT4 can ADP-ribosylate histones.
179 SIRT4 ADP-ribosylates glutamate dehydrogenase and inhibits its catalytic activity. Glutamate dehydrogenase catalyzes the conversion of glutamate to a-ketoglutarate. 179, 180 Yang et al. 181 reported that SIRT3 and SIRT4 are required for cell viability in response to genotoxic stress along with nicotinamide phosphoribosyltransferase to maintain NAD þ levels within mitochondria. To date, there are no systematic studies evaluating the role of SIRT4 in cancer, although Bradbury et al. 41 revealed that SIRT4 levels are consistently down in acute myeloid leukemia samples. Speculatively, as SIRT4 regulates a-ketoglutarate production from glutamate, we wonder what role SIRT4 may have on a-ketoglutarate-dependent enzymes that have been shown to be involved in tumorigenesis, such as the TET enzymes and jmjC histone demethylases. 182, 183 Metabolic dysfunction leading to abnormal epigenetic regulation and ultimately tumorigenesis has a precedent, as is seen with isocitrate dehydrogenase mutations in several types of cancers.
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SIRT5
Mitochondrial SIRT5 is perhaps the most unusual of sirtuins, as it possess NAD þ -dependent deacetylase as well as deacylase (demalonylase and desuccinylase) activities. 4 The best studied substrate of SIRT5 is carbamoyl phosphate synthetase 1 for the rate-limiting step in urea synthesis. Several groups have demonstrated that SIRT5 can deacetylate, demalonylate and desuccinylate carbamoyl phosphate synthetase 1. 4, 186, 187 Deacetylation of carbamoyl phosphate synthetase 1 activates its enzymatic activity, which promotes the production of urea and clearance of excessive ammonia from the cell. The biological significance of demolonylation and desuccinylation of carbamoyl phosphate synthetase 1 by SIRT5 remains unknown. 188 To date, there are no studies evaluating the role of SIRT5 in tumorigenesis.
SIRT6
Biochemical overview SIRT6 is a chromatin-bound NAD þ -dependent deacetylase and ADP-ribosyltransferase. 189 Its major histone substrates are H3K9 and H3K56. 190, 191 Michisita et al. 190 showed that SIRT6 associates with telomeres and deacetylates H3K9 to maintain proper telomeric chromatin, and disruption of telomere functions likely accounts for the premature aging phenotype observed in SIRT6 À / À mice. 192 SIRT6 has an integral role in DNA repair pathways including BER, 192 HR 193, 194 and NHEJ. 195, 196 SIRT6 can ADP-ribosylate PARP1, leading to its activation and promotion of double-strand break repair. 196 Intriguingly, overexpression of SIRT6, but not SIRT1, increases NHEJ and HR repair efficiency in nonmalignant cells. 196 Kawahara et al. 197 demonstrated that SIRT6 is recruited with NF-kB to deacetylate H3K9 and silence its target genes. SIRT6 is also a corepressor of HIF1 and represses expression of the genes involved in energy metabolism by deacetylating H3K9.
198
SIRT6 and cancer Forced expression of SIRT6 induces apoptosis of cancer cells but not in nontransformed cells.
199 SIRT6-mediated apoptosis of cancer cells requires its ADP-ribosyltransferase, but not deacetylase, activity, as well as the intact ataxia telangiectasia mutated (ATM) and p53 pathways. 199 Mice with constitutive SIRT6 knockout display genetic instability and die of a premature aging syndrome B25 days postnatally. 192 Using a conditional gene knock-out strategy, Sebastian et al. 200 very recently demonstrated a role of SIRT6 in tumor suppression. These authors revealed that loss of SIRT6 is sufficient to transform immortalized mouse embryonic fibroblasts. Conditional knockout of SIRT6 in the intestine of APC min/ þ mice results in increased tumor incidence, in part by derepression of Myc activity and activation of aerobic glycolysis. They further showed that SIRT6 is frequently deleted and its expression is significantly reduced in human cancer samples. Together with SIRT6's roles in genome maintenance, the data so far suggest that SIRT6 may act as a tumor suppressor.
SIRT7
Biochemical overview SIRT7 is primarily a deacetylase and is localized to the nucleolus as well as the nucleus. 3 Within nucleoli, SIRT7 regulates ribosomal DNA gene expression in part by activating RNA polymerase I.
201
SIRT7 deacetylates H3K18, specifically, to repress transcription.
202
SIRT7 is also shown to deacetylate p53 in vitro and in vivo, and SIRT7 ablation increases p53-mediated apoptosis.
203
SIRT7 and cancer Several groups showed that SIRT7 is elevated in human cancers of breast, 204 thyroid 205 and liver 206 origin. Ford et al. 201 demonstrated that knockdown of SIRT7 inhibits cell growth and induces apoptosis. Barber et al. 202 showed that knockdown of SIRT7 in cancer cell lines reduces cell growth both in vitro and in vivo, and demonstrated a novel oncogenic mechanism of SIRT7 by deacetylating H3K18. Interestingly, many different cancers display global hypoacetylation of H3K18, which is associated with a poor prognosis in prostate cancers. 207, 208 Viral oncogenes can stimulate hypoacetylation of H3K18. 209, 210 Consistently, Barber et al. 202 showed that knockdown of SIRT7 abolishes adenoviral E1A-mediated proliferation and transformation of fibroblasts. These studies point to a growth advantage that SIRT7 renders cancer cells. Further in vivo studies should be undertaken to evaluate roles of SIRT7 in cancer in the future.
Functions of sirtuins in cancer M Roth and WY Chen CONCLUDING REMARKS Studies of sirtuins are rapidly growing in the field of cancer and other diseases. Sirtuins are generally involved in stress response, DNA damage repair and metabolism. SIRT1, SIRT2 and SIRT3 appear to have both roles in tumor inhibition and promotion. Despite the controversy, it appears that SIRT1 has a consistent role in mediating cancer cell survival, in particular for drug resistance, and that SIRT6 has more pronounced roles in tumor suppression. Currently, both sirtuin activators and inhibitors have been developed or under development, and they may be suited for distinct therapeutic purposes. 211 For cancer treatment, inhibitors like tenovin-6 212 and cambinol, 104 which targets both SIRT1 and SIRT2, have shown antitumor effects in vivo. However, sirtuin modulators are in general not specific and potent enough. Given the complex roles of each sirtuin, future effort is needed to develop more selective sirtuin modulators for human use to treat cancer or other diseases. We expect to see continued rapid growth in sirtuin research in coming years, which will help us better understand functions of this family of proteins for the good of human health.
